Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Charles River Laboratories Intl (CRL)

Charles River Laboratories Intl (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

What Are Wall Street Analysts' Target Price for Charles River Laboratories Stock?

Wilmington, Massachusetts-based Charles River Laboratories International, Inc. (CRL) provides drug discovery, non-clinical development, and safety testing services. Valued at $8.1 billion by market cap, the company offers animal research models in research and development for new drugs, devices, and therapies, serving pharmaceutical and biotechnology companies, hospitals, and academic institutions worldwide.

Shares of this pharmaceutical company have underperformed the broader market over the past year. CRL has declined marginally over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 11.7%. In 2026, CRL’s stock fell 17.7%, compared to the SPX’s marginal rise on a YTD basis. 

Fundamentals

See More
  • Market Capitalization, $K 8,083,072
  • Shares Outstanding, K 49,215
  • Annual Sales, $ 4,050 M
  • Annual Income, $ 22,200 K
  • EBIT $ 555 M
  • EBITDA $ 1,132 M
  • 60-Month Beta 1.63
  • Price/Sales 1.94
  • Price/Cash Flow 7.20
  • Price/Book 2.45

Options Overview Details

View History
  • Implied Volatility 44.86% (-2.20%)
  • Historical Volatility 49.91%
  • IV Percentile 59%
  • IV Rank 23.36%
  • IV High 86.39% on 04/11/25
  • IV Low 32.21% on 06/18/25
  • Expected Move (DTE 28) 14.10 (8.35%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 2,025
  • Volume Avg (30-Day) 1,597
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 18,199
  • Open Int (30-Day) 8,098
  • Expected Range 154.82 to 183.02

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 2.52
  • Number of Estimates 6
  • High Estimate 2.67
  • Low Estimate 2.38
  • Prior Year 2.34
  • Growth Rate Est. (year over year) +7.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
146.33 +15.44%
on 02/18/26
228.39 -26.04%
on 01/22/26
-49.27 (-22.58%)
since 01/20/26
3-Month
146.33 +15.44%
on 02/18/26
228.88 -26.20%
on 01/13/26
+6.84 (+4.22%)
since 11/20/25
52-Week
91.86 +83.89%
on 04/11/25
228.88 -26.20%
on 01/13/26
+6.67 (+4.11%)
since 02/20/25

Most Recent Stories

More News
What Are Wall Street Analysts' Target Price for Charles River Laboratories Stock?

Charles River Laboratories has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.

XLV : 156.82 (-0.28%)
$SPX : 6,909.51 (+0.69%)
CRL : 168.92 (+2.85%)
CRL Q4 Deep Dive: Flat Sales and Margin Pressures as Biotech Demand Recovers

CRL Q4 Deep Dive: Flat Sales and Margin Pressures as Biotech Demand Recovers

CRL : 168.92 (+2.85%)
Stocks Rally on Signs of US Economic Resilience

The S&P 500 Index ($SPX ) (SPY ) today is up +0.84%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.63%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.20%. March E-mini S&P futures (ESH26...

AMAT : 375.38 (+1.50%)
B : 47.96 (-1.22%)
KNF : 90.70 (+2.76%)
HL : 24.02 (+5.40%)
GPN : 82.47 (+2.77%)
CDE : 24.63 (+2.37%)
ADI : 355.03 (+2.82%)
GLBE : 36.08 (-0.44%)
$IUXX : 25,012.62 (+0.87%)
ASML : 1,469.59 (+0.73%)
ZNH26 : 112-300s (-0.03%)
ESH26 : 6,923.25s (+0.67%)
Stocks Climb on Solid US Economic News and Easing AI Jitters

The S&P 500 Index ($SPX ) (SPY ) today is up +0.36%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.47%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.40%. March E-mini S&P futures (ESH26...

B : 47.96 (-1.22%)
KNF : 90.70 (+2.76%)
HL : 24.02 (+5.40%)
GPN : 82.47 (+2.77%)
CDE : 24.63 (+2.37%)
ADI : 355.03 (+2.82%)
DDOG : 115.66 (-4.10%)
GLBE : 36.08 (-0.44%)
$IUXX : 25,012.62 (+0.87%)
FIGR : 29.12 (-11.57%)
ZNH26 : 112-300s (-0.03%)
ESH26 : 6,923.25s (+0.67%)
Charles River Laboratories (NYSE:CRL) Beats Q4 CY2025 Sales Expectations

Charles River Laboratories (NYSE:CRL) Beats Q4 CY2025 Sales Expectations

CRL : 168.92 (+2.85%)
Charles River: Q4 Earnings Snapshot

Charles River: Q4 Earnings Snapshot

CRL : 168.92 (+2.85%)
Charles River Laboratories Announces Executive Appointments

Glenn G. Coleman Will Join Charles River as Corporate Executive Vice President and Chief Financial Officer Kerry Dailey Will Join Charles...

CRL : 168.92 (+2.85%)
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance

– Fourth-Quarter Revenue of $994.2 Million and Full-Year Revenue of $4.02 Billion – – Fourth-Quarter GAAP Loss per Share of $(5.62) and Non-GAAP...

CRL : 168.92 (+2.85%)
Charles River Laboratories (CRL) Q4 Earnings: What To Expect

Charles River Laboratories (CRL) Q4 Earnings: What To Expect

CRL : 168.92 (+2.85%)
1 S&P 500 Stock with Competitive Advantages and 2 We Ignore

1 S&P 500 Stock with Competitive Advantages and 2 We Ignore

FITB : 53.62 (+1.36%)
CRL : 168.92 (+2.85%)
ACN : 215.35 (+0.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research...

See More

Key Turning Points

3rd Resistance Point 183.89
2nd Resistance Point 177.91
1st Resistance Point 173.41
Last Price 168.92
1st Support Level 162.94
2nd Support Level 156.96
3rd Support Level 152.47

See More

52-Week High 228.88
Fibonacci 61.8% 176.54
Last Price 168.92
Fibonacci 50% 160.37
Fibonacci 38.2% 144.20
52-Week Low 91.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar